New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...
Olverembatinib shows promise in treating SDH-deficient GISTs, a rare tumor type with limited treatment options and high relapse risk. The phase 1b study demonstrated a 23.1% objective response rate ...
GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment. Recent advancements in GIST treatment include multiple TKIs, such as Sutent, ...
Verywell Health on MSN
The 3 types of ovarian cancer and how they are different
Medically reviewed by Renita White, MD Key Takeaways Epithelial ovarian carcinoma is the most common type of ovarian cancer.Germ cell tumors often affect teenagers and young adults.Stromal tumors are ...
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models ...
Hoth Therapeutics reported interim trial results showing all patients improved by Week 6, with reduced disease severity, ...
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results